Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Rossi, Davide; Terzi-di-Bergamo, Lodovico; De Paoli, Lorenzo; Cerri, Michaela; Ghilardi, Guido; Chiarenza, Annalisa; Bulian, Pietro; Visco, Carlo; Romana Mauro, Francesca; Morabito, Fortunato; Cortelezzi, Agostino; Zaja, Francesco; Forconi, Francesco; Laurenti, Luca; Del Giudice, Ilaria; Gentile, Massimo; Donatella Vincelli, Iolanda; Motta, Marina; Coscia, Marta; Matteo Rigolin, Gian; Tedeschi, Alessandra; Neri, Antonino; Marasca, Roberto; Perbellini, Omar; Moreno, Carol; Del Poeta, Giovanni; Massaia, Massimo; Luigi Zinzani, Pier; Montillo, Marco; Cuneo, Antonio; Gattei, Valter; Foà, Robin; Gaïdano, Gianluca

doi:10.1182/blood-2015-05-647925

Public

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Published in Blood • Aug 15, 2015

Authors:

Davide Rossi

Lodovico Terzi-di-Bergamo

Lorenzo De Paoli

Abstract

Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain the maximum benefit from FCR. In this observational m...

Subject

IGHV@

Fludarabine

Chronic lymphocytic leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!